305 Per Cent Returns: Leading Hospital Chain Delivers 51.8 Per Cent PAT Growth; Stock Down 6.61 Per Cent
Net profit surged 51.8 per cent YoY to Rs 372.3 crore, up from Rs 245.3 crore in the same quarter last year.
Apollo Hospitals reported a robust financial performance in Q3 FY25, with a significant rise in profitability and strong revenue growth. However, despite the impressive numbers, the stock witnessed a sharp decline of 6.61 per cent to Rs 6,314.00, as investors engaged in profit booking following the earnings announcement.
Financial Performance
Revenue from operations increased by 13.9 per cent YoY to Rs 5,526.9 crore, compared to Rs 4,850.6 crore in Q3 FY24. Meanwhile, Net profit surged 51.8 per cent YoY to Rs 372.3 crore, up from Rs 245.3 crore in the same quarter last year.
EBITDA (operating profit) soared 24.1 per cent YoY to Rs 761.5 crore, compared to Rs 613.7 crore in Q3 FY24. Company’s EBITDA margin expanded to 110 basis points (bps) to 13.8% in Q3FY25, from 12.7% in Q3 FY24.
Apollo Hospitals reaffirmed its commitment to expansion, stating that it is on track to add 3,512 beds over the next 3 to 4 years, starting from FY26. The company’s Board of Directors declared an interim dividend of Rs 9 per share for FY25. The record date for the dividend has been set as February 15, 2025, with the payout scheduled on or before February 28, 2025.
DSIJ's 'Large Rhino' service recommends blue chip stocks of Large Cap companies that have leadership positions in their category. If this interests you, do download the service details here.
Stock Price Performance
Apollo Hospitals' stock has declined 2.28 per cent over the past one year, underperforming the Nifty 50, which gained 5.83 per cent during the same period. However, the company has delivered impressive multibagger returns of 305.91 per cent over the last five years. The company currently holds a market capitalization of Rs 97,285 crore.
About the Company
Founded as India’s first corporate hospital, Apollo Hospitals has been a pioneer in private healthcare in the country. Over the years, it has evolved into Asia’s leading integrated healthcare services provider, with a strong presence across hospitals, pharmacies, primary care & diagnostic clinics, and retail health models.
Disclaimer: This article is for informational purposes only and not an investment advice.